You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

mHSPC

Showing 1 - 25 of 38
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Nanjing (6-month course of antiandrogen drugs, Long-term course of

Recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • 6-month course of antiandrogen drugs
  • Long-term course of antiandrogen drugs
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Jul 13, 2023

High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) Trial (dalpiciclib isethionate tablets; abiraterone acetate

Not yet recruiting
  • High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
  • dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
  • placebo; abiraterone acetate tablets; prednisone tablets
  • (no location specified)
Oct 20, 2023

Learn More About How Safe Darolutamide is Under Real-world

Not yet recruiting
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  • No Intervention
  • Multiple Locations, Japan
    Many Locations
Aug 24, 2023

Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemo Effect Trial in Nanjing (Docetaxel, Rezvilutamide)

Recruiting
  • Metastatic Prostate Cancer
  • +2 more
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Aug 2, 2023

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial (Standard ADT (androgen deprivation therapy), Standard Darolutamide,

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • Standard ADT (androgen deprivation therapy)
  • +2 more
  • (no location specified)
Jan 6, 2023

Cohort Studies Trial in Jinan (apantamide+docetaxel+ADT, apantamide+ADT treatment)

Recruiting
  • Cohort Studies
  • Jinan, Shandong, China
    Qilu hospital
Feb 3, 2023

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Milano, Milan (APA + ADT, Local Treatmetn RT or RP)

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
  • APA + ADT
  • Local Treatmetn RT or RP
  • Milano, Lombardia, Italy
  • +2 more
Jan 17, 2023

Prostate Cancer, Castrate Resistant Prostate Cancer Trial (Enzalutamide 40 MG, Docetaxel injection)

Not yet recruiting
  • Prostate Cancer
  • Castrate Resistant Prostate Cancer
  • Enzalutamide 40 MG
  • Docetaxel injection
  • (no location specified)
Jan 27, 2023

Prostate Cancer, Prostate Carcinoma, Metastatic Prostate Cancer Trial (Olaparib tablet, Abiraterone acetate, Prednisone tablet)

Not yet recruiting
  • Prostate Cancer
  • +2 more
  • Olaparib tablet
  • +2 more
  • (no location specified)
Dec 7, 2021

Metastatic Hormone Sensitive Prostate Cancer Trial in China (Enzalutamide, Placebo, Androgen deprivation therapy (ADT))

Active, not recruiting
  • Metastatic Hormone Sensitive Prostate Cancer
  • Beijing, China
  • +29 more
Jan 7, 2023

Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Boston (Apalutamide

Not yet recruiting
  • Prostate Adenocarcinoma
  • +2 more
  • Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
  • Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jan 4, 2023

Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer Trial in Shanghai (drug, procedure, radiation)

Not yet recruiting
  • Metastatic Prostate Cancer
  • Castration-Sensitive Prostate Cancer
  • Shanghai, Shanghai, China
  • +1 more
Feb 4, 2023

Prostate Cancer Metastatic Trial in New York (REGN2810, Degarelix, Leuprolide Acetate)

Recruiting
  • Prostate Cancer Metastatic
  • New York, New York
    Columbia University Irving Medical Center
Mar 22, 2022

Apalutamide in Metastatic Hormone Sensitive Prostate Cancer

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    • Cardiff, United Kingdom
    • +4 more
    Aug 25, 2023

    Metastatic Hormone Sensitive Prostate Cancer Treated With

    Not yet recruiting
    • Metastatic Hormone-sensitive Prostate Cancer
    • Innsbruck, Austria
    • +42 more
    Jun 5, 2023

    Metastatic Hormone-Sensitive Prostate Cancer Trial in China (biological, drug, procedure, other)

    Active, not recruiting
    • Metastatic Hormone-Sensitive Prostate Cancer
    • Pembrolizumab
    • +3 more
    • Beijing, Beijing, China
    • +23 more
    Sep 30, 2022

    Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 Trial (Pharmacotherapy

    Not yet recruiting
    • Castration-Sensitive Prostate Carcinoma
    • +4 more
    • Pharmacotherapy Discontinuation
    • +3 more
    • (no location specified)
    Feb 11, 2022

    Metastatic Prostate Cancer Trial in Guangzhou (Metformin)

    Not yet recruiting
    • Metastatic Prostate Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Jun 8, 2021

    Prostate Cancer Trial in Worldwide (Apalutamide, Placebo, Androgen Deprivation Therapy (ADT))

    Active, not recruiting
    Has Results
    • Prostate Cancer
    • Homewood, Alabama
    • +228 more
    Aug 2, 2022

    Based Discrete Choice Experiment Study in Prostate Cancer Study

    Completed
    • Prostate Cancer
    • Metastatic Hormone-sensitive Prostate Cancer
      • Durham, North Carolina
        Duke Clinical Research Institute
      Jan 10, 2023

      Metastatic Hormone Sensitive Prostate Cancer Trial in Worldwide (Enzalutamide, Placebo)

      Active, not recruiting
      Has Results
      • Metastatic Hormone Sensitive Prostate Cancer
      • Homewood, Alabama
      • +202 more
      Jul 29, 2022

      Metastatic Hormone-Sensitive Prostate Cancer Trial in Worldwide (biological, drug, procedure, other)

      Active, not recruiting
      • Metastatic Hormone-Sensitive Prostate Cancer
      • Pembrolizumab
      • +3 more
      • Anchorage, Alaska
      • +212 more
      Aug 18, 2022

      Metastatic Hormone-sensitive Prostate Cancer Trial in United States (Darolutamide (BAY1841788, Nubeqa), ADT)

      Recruiting
      • Metastatic Hormone-sensitive Prostate Cancer
      • Darolutamide (BAY1841788, Nubeqa)
      • ADT
      • Homewood, Alabama
      • +11 more
      Jan 13, 2023

      Learn About Novel Hormonal Therapies in People With Metastatic

      Not yet recruiting
      • Prostatic Neoplasms
      • Novel hormonal therapy
      • New York, New York
        Pfizer Inc
      Oct 2, 2023

      Learn About Novel Hormonal Therapies for Metastatic

      Not yet recruiting
      • Prostatic Neoplasms
      • Novel hormonal therapy
      • New York, New York
        Pfizer Inc
      Nov 21, 2023